Revolutionary Drug Doubles Survival to 13 Months vs. Standard Chemotherapy
Pancreatic cancer, the deadliest of all major malignancies, has just seen a seismic shift in treatment: a newly approved targeted therapy, adagrasib (brand name Krazati), has doubled median overall survival ... Read More